Skip to main content
SpringerLink
Log in

Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course

  • Original Paper
  • Published:
Acta Neuropathologica Aims and scope Submit manuscript

Abstract

The “isomorphic subtype of diffuse astrocytoma” was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R et al (2016) MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 48:273–282. https://doi.org/10.1038/ng.3500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Blumcke I, Aronica E, Urbach H, Alexopoulos A, Gonzalez-Martinez JA (2014) A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol 128:39–54. https://doi.org/10.1007/s00401-014-1288-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Blumcke I, Luyken C, Urbach H, Schramm J, Wiestler O (2004) An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol 107:381–388. https://doi.org/10.1007/s00401-004-0833-3

    Article  PubMed  Google Scholar 

  4. Blumcke I, Spreafico R, Haaker G, Coras R, Kobow K, Bien CG et al (2017) Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery. New Engl J Med 377:1648–1656. https://doi.org/10.1056/NEJMoa1703784

    Article  PubMed  Google Scholar 

  5. Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA et al (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121

    Article  CAS  PubMed  Google Scholar 

  6. Capper D, Engel NW, Stichel D, Lechner M, Glöss S, Schmid S et al (2018) DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathol 136:255–271. https://doi.org/10.1007/s00401-018-1854-7

    Article  CAS  PubMed  Google Scholar 

  7. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D et al (2018) DNA methylation-based classification of central nervous system tumours. Nature 555:469–474. https://doi.org/10.1038/nature26000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Capper D, Weißert S, Balss J, Habel A, Meyer J, Jäger D et al (2010) Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathol 20:245–254. https://doi.org/10.1111/j.1750-3639.2009.00352.x

    Article  CAS  PubMed  Google Scholar 

  9. Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118:599–601. https://doi.org/10.1007/s00401-009-0595-z

    Article  CAS  PubMed  Google Scholar 

  10. Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang T-C et al (2008) c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther 7:1758–1764. https://doi.org/10.4161/cbt.7.11.6722

    Article  CAS  PubMed  Google Scholar 

  11. Ciceri G, Dehorter N, Sols I, Huang ZJ, Maravall M, Marin O (2013) Lineage-specific laminar organization of cortical GABAergic interneurons. Nat Neurosci 16:1199–1210. https://doi.org/10.1038/nn.3485

    Article  CAS  PubMed  Google Scholar 

  12. Deng MY, Sill M, Chiang J, Schittenhelm J, Ebinger M, Schuhmann MU et al (2018) Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathol 136:239–253. https://doi.org/10.1007/s00401-018-1865-4

    Article  CAS  PubMed  Google Scholar 

  13. Ellison DW, Hawkins C, Jones DTW, Onar-Thomas A, Pfister SM, Reifenberger G et al (2019) cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathol Online first. https://doi.org/10.1007/s00401-019-01987-0

    Article  Google Scholar 

  14. Gonda TJ, Buckmaster C, Ramsay RG (1989) Activation of c-myb by carboxy-terminal truncation: relationship to transformation of murine haemopoietic cells in vitro. EMBO J 8:1777–1783. https://doi.org/10.1002/j.1460-2075.1989.tb03571.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555:321–327. https://doi.org/10.1038/nature25480

    Article  CAS  PubMed  Google Scholar 

  16. Hansen KD, Aryee M (2012) IlluminaHumanMethylation450kmanifest: annotation for Illumina’s 450k methylation arrays. R package version. https://doi.org/10.18129/B9.bioc.IlluminaHumanMethylation450kmanifest

    Article  Google Scholar 

  17. Hansen KD, Aryee M (2016) IlluminaHumanMethylationEPICmanifest: manifest for Illumina’s EPIC methylation arrays. R package version. https://doi.org/10.18129/B9.bioc.IlluminaHumanMethylationEPICmanifest

    Article  Google Scholar 

  18. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1010 diffuse gliomas. Acta Neuropathol 118:469–474. https://doi.org/10.1007/s00401-009-0561-9

    Article  PubMed  Google Scholar 

  19. Ho AS, Kannan K, Roy DM, Morris LGT, Ganly I, Katabi N et al (2013) The mutational landscape of adenoid cystic carcinoma. Nat Genet 45:791–798. https://doi.org/10.1038/ng.2643

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hou Y, Pinheiro J, Sahm F, Reuss DE, Schrimpf D, Stichel D et al (2019) Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathol. https://doi.org/10.1007/s00401-019-01969-2

    Article  PubMed  Google Scholar 

  21. Hovestadt V, Remke M, Kool M, Pietsch T, Northcott P, Fischer R et al (2013) Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 125:913–916. https://doi.org/10.1007/s00401-013-1126-5

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hovestadt V, Zapatka M conumee: enhanced copy-number variation analysis using Illumina DNA methylation arrays. R package version 1.9.0. https://doi.org/10.18129/b9.bioc.conumee

  23. Johann PD, Bens S, Oyen F, Wagener R, Giannini C, Perry A et al (2018) Sellar region atypical teratoid/rhabdoid tumors (ATRT) in adults display DNA methylation profiles of the ATRT-MYC subgroup. Am J Surg Pathol 42:506–511. https://doi.org/10.1097/PAS.0000000000001023

    Article  PubMed  Google Scholar 

  24. Jones DTW, Hutter B, Jager N, Korshunov A, Kool M, Warnatz H-J et al (2013) Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932. https://doi.org/10.1038/ng.2682

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M et al (2017) Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol 22:160–173. https://doi.org/10.1093/neuonc/nox141

    Article  CAS  Google Scholar 

  26. Jones DTW, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K et al (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673. https://doi.org/10.1158/0008-5472.CAN-08-2097

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kanei-Ishii C, MacMillan EM, Nomura T, Sarai A, Ramsay RG, Aimoto S et al (1992) Transactivation and transformation by Myb are negatively regulated by a leucine-zipper structure. Proc Natl Acad Sci 89:3088–3092. https://doi.org/10.1073/pnas.89.7.3088

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Koelsche C, Mynarek M, Schrimpf D, Bertero L, Serrano J, Sahm F et al (2018) Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathol 136:327–337. https://doi.org/10.1007/s00401-018-1871-6

    Article  CAS  PubMed  Google Scholar 

  29. Li B, Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform 12:323. https://doi.org/10.1186/1471-2105-12-323

    Article  CAS  Google Scholar 

  30. Lin Y-C, Kuo M-W, Yu J, Kuo H-H, Lin R-J, Lo W-L et al (2008) c-Myb is an evolutionary conserved miR-150 target and miR-150/c-Myb interaction is important for embryonic development. Mol Biol Evol 25:2189–2198. https://doi.org/10.1093/molbev/msn165

    Article  CAS  PubMed  Google Scholar 

  31. Liu Y, Easton J, Shao Y, Maciaszek J, Wang Z, Wilkinson MR et al (2017) The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat Genet 49:1211–1218. https://doi.org/10.1038/ng.3909

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, rev. 4th edn. IARC, Lyon

    Google Scholar 

  33. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al (2014) International Society of Neuropathology-Haarlem Consensus Guidelines, for nervous system tumor classification and grading. Brain Pathol 24:671–672. https://doi.org/10.1111/bpa.12171

    Article  PubMed  Google Scholar 

  34. Oh IH, Reddy EP (1999) The myb gene family in cell growth, differentiation and apoptosis. Oncogene 18:3017–3033. https://doi.org/10.1038/sj.onc.1202839

    Article  CAS  PubMed  Google Scholar 

  35. Pajtler KW, Witt H, Sill M, Jones DTW, Hovestadt V, Kratochwil F et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27:728–743. https://doi.org/10.1016/j.ccell.2015.04.002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G (2009) Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci 106:18740–18744. https://doi.org/10.1073/pnas.0909114106

    Article  PubMed  PubMed Central  Google Scholar 

  37. Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD et al (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131:833–845. https://doi.org/10.1007/s00401-016-1539-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Quelen C, Lippert E, Struski S, Demur C, Soler G, Prade N et al (2011) Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. Blood 117:5719–5722. https://doi.org/10.1182/blood-2011-01-333013

    Article  CAS  PubMed  Google Scholar 

  39. Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, Rich BE, Schumacher SE et al (2013) Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci 110:8188–8193. https://doi.org/10.1073/pnas.1300252110

    Article  PubMed  PubMed Central  Google Scholar 

  40. Reinhardt A, Stichel D, Schrimpf D, Sahm F, Korshunov A, Reuss DE et al (2018) Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 136:273–291. https://doi.org/10.1007/s00401-018-1837-8

    Article  CAS  PubMed  Google Scholar 

  41. Reuss DE, Kratz A, Sahm F, Capper D, Schrimpf D, Koelsche C et al (2015) Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 130:407–417. https://doi.org/10.1007/s00401-015-1454-8

    Article  CAS  PubMed  Google Scholar 

  42. Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G et al (2011) Integrative genomics viewer. Nat Biotechnol 29:24–26. https://doi.org/10.1038/nbt.1754

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S et al (2014) Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 128:551–559. https://doi.org/10.1007/s00401-014-1326-7

    Article  CAS  PubMed  Google Scholar 

  44. Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S et al (2017) DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 18:682–694. https://doi.org/10.1016/S1470-2045(17)30155-9

    Article  CAS  PubMed  Google Scholar 

  45. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405. https://doi.org/10.1007/s00401-011-0802-6

    Article  CAS  PubMed  Google Scholar 

  46. Schramm J, Luyken C, Urbach H, Fimmers R, Blumcke I (2004) Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery 55:340–347. https://doi.org/10.1227/01.NEU.0000129546.38675.1B

    Article  PubMed  Google Scholar 

  47. Schurr J, Coras R, Rössler K, Pieper T, Kudernatsch M, Holthausen H et al (2017) Mild malformation of cortical development with oligodendroglial hyperplasia in frontal lobe epilepsy: a new clinico-pathological entity. Brain Pathol 27:26–35. https://doi.org/10.1111/bpa.12347

    Article  CAS  PubMed  Google Scholar 

  48. Sievers P, Stichel D, Schrimpf D, Sahm F, Koelsche C, Reuss DE et al (2018) FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathol 136:293–302. https://doi.org/10.1007/s00401-018-1882-3

    Article  CAS  PubMed  Google Scholar 

  49. Stichel D, Schrimpf D, Casalini B, Meyer J, Wefers AK, Sievers P et al (2019) Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. Acta Neuropathol First Online. https://doi.org/10.1007/s00401-019-02039-3

    Article  Google Scholar 

  50. Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DTW, Capper D et al (2016) New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164:1060–1072. https://doi.org/10.1016/j.cell.2016.01.015

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. https://doi.org/10.1016/j.ccr.2012.08.024

    Article  CAS  PubMed  Google Scholar 

  52. Suzuki K, Suzuki Y, Hama A, Muramatsu H, Nakatochi M, Gunji M et al (2017) Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. Leukemia 31:1629–1633. https://doi.org/10.1038/leu.2017.101

    Article  CAS  PubMed  Google Scholar 

  53. Takahashi T, Nakagoshi H, Sarai A, Nomura N, Yamamoto T, Ishii S (1995) Human A-myb gene encodes a transcriptional activator containing the negative regulatory domains. FEBS Lett 358:89–96. https://doi.org/10.1016/0014-5793(94)01402-M

    Article  CAS  PubMed  Google Scholar 

  54. Tatevossian R, Tang B, Dalton J, Forshew T, Lawson A, Ma J et al (2010) MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas. Acta Neuropathol 120:731–743. https://doi.org/10.1007/s00401-010-0763-1

    Article  PubMed  PubMed Central  Google Scholar 

  55. Urbach H, Binder D, von Lehe M, Podlogar M, Bien CG, Becker A et al (2007) Correlation of MRI and histopathology in epileptogenic parietal and occipital lobe lesions. Seizure 16:608–614. https://doi.org/10.1016/j.seizure.2007.04.009

    Article  PubMed  Google Scholar 

  56. Weston K (1998) Myb proteins in life, death and differentiation. Curr Opin Genet Dev 8:76–81. https://doi.org/10.1016/S0959-437X(98)80065-8

    Article  CAS  PubMed  Google Scholar 

  57. Xiao C, Calado DP, Galler G, Thai T-H, Patterson HC, Wang J et al (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131:146–159. https://doi.org/10.1016/j.cell.2007.07.021

    Article  CAS  PubMed  Google Scholar 

  58. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. New Engl J Med 360:765–773. https://doi.org/10.1056/NEJMoa0808710

    Article  CAS  PubMed  Google Scholar 

  59. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B et al (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45:602–612. https://doi.org/10.1038/ng.2611

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zhao H, Kalota A, Jin S, Gewirtz AM (2009) The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood 113:505. https://doi.org/10.1182/blood-2008-01-136218

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank K. Böhmer, A. Habel, S. Kocher, U. Lass, K. Lindenberg, R. Quan, S. Sprengart, U. Vogel, M. Werner and V. Zeller for excellent technical assistance. We thank the Genomics and Proteomics Core Facility of the German Cancer Research Center (DKFZ) for the performance of DNA methylation analyses. A.K. Wefers is a fellow of the Physician Scientist-Program of the Medical Faculty of Heidelberg. This study was supported by an International League against Epilepsy (ILAE) Grant to D. Capper. I. Blumcke was supported by the European Union (FP6 DESIRE Grant Agreement #602531). M. Mittelbronn would like to thank the Luxembourg National Research Fund (FNR) for the support (FNR PEARL P16/BM/11192868 grant). K. Ligon is funded by the Paediatric Low Grade Astrocytoma Foundation and NCI R01CA215489. T. Jacques is funded by The Brain Tumour Charity, Children with Cancer UK, Great Ormond Street Hospital Children’s Charity, Cancer Research UK, the Olivia Hodson Cancer Fund and the National Institute of Health Research. T. Jacques’s work is partly funded by the NIHR GOSH BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. We thank the biomedical scientists in the Division of Neuropathology, the National Hospital for Neurology and Neurosurgery (NHNN) for excellent technical assistance. We also thank clinicians and neuropathologists for referring cases for molecular analysis. Part of the study was funded by the National Institute for Health Research to UCLH Biomedical research centre (BRC399/NS/RB/101410). S. Brandner and Z. Jaunmuktane are also supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. Additional funding was provided by the Brain Tumour Charity (UK) for the Everest Centre for Paediatric Low-Grade Brain Tumour Research.

Author information

Authors and Affiliations

  1. Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

    Annika K. Wefers, Damian Stichel, Daniel Schrimpf, Jochen Meyer, David E. Reuss, Annekathrin Reinhardt, Philipp Sievers, M. Belén Casalini, Azadeh Ebrahimi, Kristin Huang, Christian Koelsche, Andrey Korshunov, Felix Sahm & Andreas von Deimling

  2. Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

    Annika K. Wefers, Damian Stichel, Daniel Schrimpf, Jochen Meyer, David E. Reuss, Annekathrin Reinhardt, Philipp Sievers, M. Belén Casalini, Azadeh Ebrahimi, Kristin Huang, Andrey Korshunov, Felix Sahm & Andreas von Deimling

  3. Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany

    Annika K. Wefers, Stefan M. Pfister, Felix Sahm & David T. W. Jones

  4. Department of Neuropathology, University Hospital Erlangen, Erlangen, Germany

    Roland Coras & Ingmar Blumcke

  5. Department of Neuropathology, Sainte-Anne Hospital, Descartes University, Paris, France

    Mélanie Pages, Arnault Tauziède-Espariat & Pascale Varlet

  6. Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany

    Daniel Schwarz

  7. Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany

    Daniel Schwarz

  8. Department of Pathology, Hacettepe University Faculty of Medicine, Ankara, Turkey

    Figen Söylemezoglu

  9. Department of Cellular Pathology, Queen’s Hospital BHRUT, Romford, UK

    Ute Pohl

  10. Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham/University Hospitals Birmingham, Birmingham, UK

    Ute Pohl

  11. Department of Neurosciences and Mental Health, Laboratory of Neuropathology, Hospital de Santa Maria (CHULN, EPE), Lisbon, Portugal

    José Pimentel

  12. Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

    José Pimentel

  13. Institute of Pathology, University of Bern, Bern, Switzerland

    Ekkehard Hewer

  14. Department of Neuropathology, University of Bonn, Bonn, Germany

    Anna Japp & Albert J. Becker

  15. Department of Neuropathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK

    Abhijit Joshi

  16. Department of General Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany

    Christian Koelsche

  17. Department of Neurosurgery, Queen’s Hospital BHRUT, Romford, UK

    Hu Liang Low

  18. Neuropathology Unit, Centro Hospitalar de Universidades de Coimbra, Coimbra, Portugal

    Olinda Rebelo & Dina Marnoto

  19. Institute of Neuropathology, University of Freiburg, Freiburg, Germany

    Ori Staszewski

  20. Edinger Institute, Institute of Neurology, University of Frankfurt am Main, Frankfurt, Germany

    Michel Mittelbronn

  21. Luxembourg Center of Neuropathology (LCNP), Dudelange, Luxembourg

    Michel Mittelbronn

  22. Laboratoire National de Santé (LNS), National Center of Pathology (NCP), Dudelange, Luxembourg

    Michel Mittelbronn

  23. Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg

    Michel Mittelbronn

  24. Department of Oncology (DONC), Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg

    Michel Mittelbronn

  25. Institute of Neuropathology, University Hospital Münster, Münster, Germany

    Martin Hasselblatt

  26. Department of Neuropathology, Institute of Pathology and Neuropathology, University Hospital of Tübingen, Tübingen, Germany

    Jens Schittenhelm

  27. Center for CNS Tumours, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital of Tübingen, Tübingen, Germany

    Jens Schittenhelm

  28. Department of Paediatric Histopathology, Royal Manchester Children’s Hospital Manchester, Manchester, UK

    Edmund Cheesman

  29. Division of Pediatric Neurosurgery, Department of Surgery and Anatomy, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

    Ricardo Santos de Oliveira

  30. Department of Pediatrics, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil

    Rosane Gomes P. Queiroz & Elvis Terci Valera

  31. Abteilung Neuropathologie, Institut für klinische Pathologie, Dietrich-Bonhoeffer-Klinikum, Neubrandenburg, Germany

    Volkmar H. Hans

  32. Institut für Neuropathologie, Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany

    Volkmar H. Hans

  33. Departments of Pathology and Laboratory Medicine and Neurosurgery, Medical University of South Carolina, Charleston, SC, USA

    Adriana Olar

  34. Hollings Cancer Center, Charleston, SC, USA

    Adriana Olar

  35. Department of Oncologic Pathology, Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School, Boston, MA, USA

    Keith L. Ligon

  36. Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany

    Stefan M. Pfister

  37. Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany

    Stefan M. Pfister

  38. Division of Neuropathology, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

    Zane Jaunmuktane & Maria Thom

  39. Department of Clinical and Movement Neurosciences, UCL Institute of Neurology, London, UK

    Zane Jaunmuktane & Sebastian Brandner

  40. Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK

    Sebastian Brandner

  41. Department of Pathology, St. Jude Children’s Research Hospital, Memphis, TN, USA

    Ruth G. Tatevossian & David W. Ellison

  42. Developmental Biology and Cancer Section, UCL Great Ormond Street Institute of Child Health, London, UK

    Thomas S. Jacques

  43. Department of Pathology, Hospital Pedro Hispano, Matosinhos, Portugal

    Mrinalini Honavar

  44. Amsterdam UMC, Department of (Neuro)Pathology, University of Amsterdam, Amsterdam and Stichting Epilepsie Instellingen Nederland, Heemstede, The Netherlands

    Eleonora Aronica

  45. Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

    David T. W. Jones

  46. Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

    David Capper

  47. German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany

    David Capper

Authors
  1. Annika K. Wefers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Damian Stichel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Schrimpf
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roland Coras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mélanie Pages
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arnault Tauziède-Espariat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pascale Varlet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel Schwarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Figen Söylemezoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ute Pohl
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. José Pimentel
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jochen Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ekkehard Hewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Anna Japp
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Abhijit Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. David E. Reuss
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Annekathrin Reinhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Philipp Sievers
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. M. Belén Casalini
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Azadeh Ebrahimi
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Kristin Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Christian Koelsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Hu Liang Low
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Olinda Rebelo
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Dina Marnoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Albert J. Becker
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Ori Staszewski
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Michel Mittelbronn
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Martin Hasselblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Jens Schittenhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Edmund Cheesman
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Ricardo Santos de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Rosane Gomes P. Queiroz
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Elvis Terci Valera
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Volkmar H. Hans
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Andrey Korshunov
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Adriana Olar
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Keith L. Ligon
    View author publications

    You can also search for this author in PubMed Google Scholar

  39. Stefan M. Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

  40. Zane Jaunmuktane
    View author publications

    You can also search for this author in PubMed Google Scholar

  41. Sebastian Brandner
    View author publications

    You can also search for this author in PubMed Google Scholar

  42. Ruth G. Tatevossian
    View author publications

    You can also search for this author in PubMed Google Scholar

  43. David W. Ellison
    View author publications

    You can also search for this author in PubMed Google Scholar

  44. Thomas S. Jacques
    View author publications

    You can also search for this author in PubMed Google Scholar

  45. Mrinalini Honavar
    View author publications

    You can also search for this author in PubMed Google Scholar

  46. Eleonora Aronica
    View author publications

    You can also search for this author in PubMed Google Scholar

  47. Maria Thom
    View author publications

    You can also search for this author in PubMed Google Scholar

  48. Felix Sahm
    View author publications

    You can also search for this author in PubMed Google Scholar

  49. Andreas von Deimling
    View author publications

    You can also search for this author in PubMed Google Scholar

  50. David T. W. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  51. Ingmar Blumcke
    View author publications

    You can also search for this author in PubMed Google Scholar

  52. David Capper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Annika K. Wefers or David Capper.

Ethics declarations

Conflict of interest

D. Capper, D. T. W. Jones, A. von Deimling and S. M. Pfister declare that under the No. EP3067432A1 a patent was applied for a “DNA-methylation based method for classifying tumor species”. D. Capper and A. von Deimling are patent holders of “Methods for the diagnosis and the prognosis of a brain tumor”, the IDH1 R132H-specific antibody used in this manuscript (US 8367347 B2). The patent is under the administrative supervision of the DKFZ technology transfer office.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 569 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wefers, A.K., Stichel, D., Schrimpf, D. et al. Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathol 139, 193–209 (2020). https://doi.org/10.1007/s00401-019-02078-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-019-02078-w

Keywords

Search

Navigation